‘PANORAMA VIEW OF IN-SITU GEL AND HYDROGEL-PERSONALIZED APPROACH FOR MANAGEMENT OF VAGINAL CANDIDIASIS.’
Main Article Content
Keywords
fungal infections, vulvovaginal candidiasis, candidiasis, hydrogel, in-situ gel, azoles
Abstract
Currently, the most prevalent issue with skin health in the world is fungus-related skin infections. which has drawn the attention of scientists most is candidiasis. Fungal infections are usually mitigated with topical or systemic antifungal medication. Because it offers tailored treatment and has fewer adverse effects, topical fungal therapy is typically favored. Because of their unique structural and functional characteristics, advanced topical carriers including in-situ gels and hydrogels are employed to address biopharmaceutical issues with conventional drug delivery systems, such as poor retention and low bioavailability. These systems have the capacity to load micro and nanoparticles and can be delivered in a sol environment. They can then enter the body as a gel. According to published evidence, topical carriers of in-situ gels and hydrogels loaded with anti-fungal drugs exhibit high therapeutic effects with less harm. This study highlights current developments in innovative techniques used in in-situ gels and hydrogels to enhance the therapeutic efficacy of anti-fungal medications.
Downloads
References
1. Takalkar D, Desai N. Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis—Development and Evaluation. AAPS PharmSciTech. 2018 Apr 1;19(3):1297–307. 2. Vigani B, Rossi S, Sandri G, Bonferoni MC, Caramella CM, Ferrari F. Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes. Pharmaceutics. 2020 Sep;12(9):859. 3. Ruel-Gariépy E, Leroux JC. In situ-forming hydrogels—review of temperature-sensitive systems. European Journal of Pharmaceutics and Biopharmaceutics. 2004 Sep 1;58(2):409–26. 4. Jacob S, Nair AB, Shah J, Sreeharsha N, Gupta S, Shinu P. Emerging Role of Hydrogels in Drug Delivery Systems, Tissue Engineering and Wound Management. Pharmaceutics. 2021 Mar;13(3):357. 5. Caramella CM, Rossi S, Ferrari F, Bonferoni MC, Sandri G. Mucoadhesive and thermogelling systems for vaginal drug delivery. Advanced Drug Delivery Reviews. 2015 Sep 15;92:39–52. 6. dos Santos AM, Carvalho SG, Araujo VHS, Carvalho GC, Gremião MPD, Chorilli M. Recent advances in hydrogels as strategy for drug delivery intended to vaginal infections. International Journal of Pharmaceutics. 2020 Nov 30;590:119867. 7. Sethi G. Vulvovaginal Candidiasis. In: Ridley’s The Vulva [Internet]. John Wiley & Sons, Ltd; 2022 [cited 2023 Feb 5]. p. 74–7. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119755173.ch10 8. Ravani L, Esposito E, Bories C, Moal VLL, Loiseau PM, Djabourov M, et al. Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies. International Journal of Pharmaceutics. 2013 Oct 1;454(2):695–702. 9. Rossi S, Mori M, Vigani B, Bonferoni MC, Sandri G, Riva F, et al. A novel dressing for the combined delivery of platelet lysate and vancomycin hydrochloride to chronic skin ulcers: Hyaluronic acid particles in alginate matrices. European Journal of Pharmaceutical Sciences. 2018 Jun 15;118:87–95. 10. Mirza MohdA, Panda AK, Asif S, Verma D, Talegaonkar S, Manzoor N, et al. A vaginal drug delivery model. Drug Delivery. 2016 Oct 12;23(8):3123–34. 11. Sahoo S, Pani NR, Sahoo SK. Effect of microemulsion in topical sertaconazole hydrogel: in vitro and in vivo study. Drug Delivery. 2016 Jan 2;23(1):338–45. 12. Horowitz BJ, Edelstein SW, Lippman L. Sexual transmission of Candida. Obstet Gynecol. 1987 Jun 1;69(6):883–6. 13. Grinceviciene S, Ruban K, Bellen G, Donders GGG. Sexual behaviour and extra-genital colonisation in women treated for recurrent Candida vulvo-vaginitis. Mycoses. 2018;61(11):857–60. 14. Stein GE, Sheridan VL, Magee BB, Magee PT. Use of rDNA restriction fragment length polymorphisms to differentiate strains of Candida albicans in women with vulvovaginal candidiasis. Diagnostic Microbiology and Infectious Disease. 1991 Nov 1;14(6):459–64. 15. Tang H, Zhao W, Yu J, Li Y, Zhao C. Recent Development of pH-Responsive Polymers for Cancer Nanomedicine. Molecules. 2019 Jan;24(1):4. 16. Talaei Z, Sheikhbahaei S, Ostadi V, Ganjalikhani Hakemi M, Meidani M, Naghshineh E, et al. Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? Int J Fertil Steril. 2017;11(3):134–41. 17. Garg A, Sharma GS, Goyal AK, Ghosh G, Si SC, Rath G. Recent advances in topical carriers of anti-fungal agents. Heliyon. 2020 Aug 1;6(8):e04663. 18. Akiyama K, Shida T, Yasueda H, Mita H, Yanagihara Y, Hasegawa M, et al. Allergenicity of acid protease secreted by Candida albicans. Allergy. 1996;51(12):887–92. 19. Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, et al. Biofilms and vulvovaginal candidiasis. Colloids and Surfaces B: Biointerfaces. 2019 Feb 1;174:110–25. 20. Giraldo PC, Babula O, Gonçalves AKS, Linhares IM, Amaral RL, Ledger WJ, et al. Mannose-Binding Lectin Gene Polymorphism, Vulvovaginal Candidiasis, and Bacterial Vaginosis. Obstetrics & Gynecology. 2007 May;109(5):1123. 21. Donders G, Babula O, Bellen G, Linhares I, Witkin S. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG: An International Journal of Obstetrics & Gynaecology. 2008;115(10):1225–31. 22. Gunther LSA, Martins HPR, Gimenes F, Abreu ALP de, Consolaro MEL, Svidzinski TIE. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. Sao Paulo Med J. 2014;132:116–20. 23. Effect of Bismuth Lipophilic Nanoparticles (BisBAL NPs) on Tricho...: Ingenta Connect [Internet]. [cited 2023 Feb 9]. Available from: https://www.ingentaconnect.com/contentone/asp/jnn/2017/00000017/00000007/art00026 24. Singh VK, Anis A, Banerjee I, Pramanik K, Bhattacharya MK, Pal K. Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosis. Materials Science and Engineering: C. 2014 Nov 1;44:151–8. 25. Donders GGG, Bellen G, Mendling W. Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecol Obstet Invest. 2010;70(4):306–21. 26. Srivastava N, Patel DK, Rai VK, Pal A, Yadav NP. Development of emulgel formulation for vaginal candidiasis: Pharmaceutical characterization, in vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology. 2018 Dec 1;48:490–8. 27. Ahmed MM, Fatima F, Anwer MdK, Ibnouf EO, Kalam MA, Alshamsan A, et al. Formulation and in vitro evaluation of topical nanosponge-based gel containing butenafine for the treatment of fungal skin infection. Saudi Pharmaceutical Journal. 2021 May 1;29(5):467–77. 28. Permana AD, Utomo E, Pratama MR, Amir MuhN, Anjani QK, Mardikasari SA, et al. Bioadhesive-Thermosensitive In Situ Vaginal Gel of the Gel Flake-Solid Dispersion of Itraconazole for Enhanced Antifungal Activity in the Treatment of Vaginal Candidiasis. ACS Appl Mater Interfaces. 2021 Apr 21;13(15):18128–41. 29. History and Update on Host Defense Against Vaginal Candidiasis - Fidel - 2007 - American Journal of Reproductive Immunology - Wiley Online Library [Internet]. [cited 2023 Feb 9]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0897.2006.00450.x 30. Srikar G, Rani AP. Study on influence of polymer and surfactant on in vitro performance of biodegradable aqueous-core nanocapsules of tenofovirdisoproxil fumarate by response surface methodology. Braz J Pharm Sci [Internet]. 2019 Aug 12 [cited 2023 Feb 9];55. Available from: http://www.scielo.br/j/bjps/a/kmBkD4PB5gYBhjDYxq39Zhh/abstract/?lang=en 31. Jøraholmen MW, Johannessen M, Gravningen K, Puolakkainen M, Acharya G, Basnet P, et al. Liposomes-In-Hydrogel Delivery System Enhances the Potential of Resveratrol in Combating Vaginal Chlamydia Infection. Pharmaceutics. 2020 Dec;12(12):1203. 32. Saporiti AM, Gómez D, Levalle S, Galeano M, Davel G, Vivot W, et al. [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use]. Rev Argent Microbiol. 2001 Oct 1;33(4):217–22. 33. Zimmermann ES, Ferreira LM, Denardi LB, Sari MHM, Cervi VF, Nogueira CW, et al. Mucoadhesive gellan gum hydrogel containing diphenyl diselenide-loaded nanocapsules presents improved anti-candida action in a mouse model of vulvovaginal candidiasis. European Journal of Pharmaceutical Sciences. 2021 Dec 1;167:106011. 34. Calvo NL, Svetaz LA, Alvarez VA, Quiroga AD, Lamas MC, Leonardi D. Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative dosage form for the treatment of vaginal candidiasis. International Journal of Pharmaceutics. 2019 Feb 10;556:181–91. 35. Young G, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews [Internet]. 2001 [cited 2023 Feb 9];(4). Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000225/abstract 36. dos Santos MK, Kreutz T, Danielli LJ, De Marchi JGB, Pippi B, Koester LS, et al. A chitosan hydrogel-thickened nanoemulsion containing Pelargonium graveolens essential oil for treatment of vaginal candidiasis. Journal of Drug Delivery Science and Technology. 2020 Apr 1;56:101527. 37. Kim YT, Shin BK, Garripelli VK, Kim JK, Davaa E, Jo S, et al. A thermosensitive vaginal gel formulation with HPγCD for the pH-dependent release and solubilization of amphotericin B. European Journal of Pharmaceutical Sciences. 2010 Oct 9;41(2):399–406. 38. Kang JW, Davaa E, Kim YT, Park JS. A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel. Journal of Drug Targeting. 2010 Sep 1;18(8):637–44. 39. Osmałek T, Froelich A, Jadach B, Tatarek A, Gadziński P, Falana A, et al. Recent Advances in Polymer-Based Vaginal Drug Delivery Systems. Pharmaceutics. 2021 Jun;13(6):884. 40. Association of Thymbra capitata essential oil and chitosan (TCCH hydrogel): a putative therapeutic tool for the treatment of vulvovaginal candidosis - de‐Oliveira - 2013 - Flavour and Fragrance Journal - Wiley Online Library [Internet]. [cited 2023 Feb 9]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ffj.3144 41. Hsin YK, Thangarajoo T, Choudhury H, Pandey M, Meng LW, Gorain B. Stimuli-Responsive in situ Spray Gel of Miconazole Nitrate for Vaginal Candidiasis. Journal of Pharmaceutical Sciences. 2023 Feb 1;112(2):562–72. 42. Abourehab MAS, Rajendran RR, Singh A, Pramanik S, Shrivastav P, Ansari MJ, et al. Alginate as a Promising Biopolymer in Drug Delivery and Wound Healing: A Review of the State-of-the-Art. International Journal of Molecular Sciences. 2022 Jan;23(16):9035. 43. Wu X, Zhang S, Li H, Shen L, Dong C, Sun Y, et al. Biofilm Formation of Candida albicans Facilitates Fungal Infiltration and Persister Cell Formation in Vaginal Candidiasis. Frontiers in Microbiology [Internet]. 2020 [cited 2023 Feb 9];11. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2020.01117 44. Augusto de Castro M, Henrique Reis P, Fernandes C, Geraldo de Sousa R, Toshio Inoue T, Ligório Fialho S, et al. Thermoresponsive in-situ gel containing hyaluronic acid and indomethacin for the treatment of corneal chemical burn. International Journal of Pharmaceutics. 2023 Jan 25;631:122468. 45. Kolawole OM, Cook MT. In situ gelling drug delivery systems for topical drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2023 Mar 1;184:36–49. 46. Abd Ellah NH, Abdel-Aleem JA, Abdo MN, Abou-Ghadir OF, Zahran KM, Hetta HF. Efficacy of ketoconazole gel-flakes in treatment of vaginal candidiasis: Formulation, in vitro and clinical evaluation. International Journal of Pharmaceutics. 2019 Aug 15;567:118472. 47. Abdellatif MM, Khalil IA, Elakkad YE, Eliwa HA, Samir TM, Al-Mokaddem AK. Formulation and Characterization of Sertaconazole Nitrate Mucoadhesive Liposomes for Vaginal Candidiasis. International Journal of Nanomedicine. 2020 Dec 31;15:4079–90. 48. Rawat PS, Ravi PR, Mir SI, Khan MS, Kathuria H, Katnapally P, et al. Design, Characterization and Pharmacokinetic–Pharmacodynamic Evaluation of Poloxamer and Kappa-Carrageenan-Based Dual-Responsive In Situ Gel of Nebivolol for Treatment of Open-Angle Glaucoma. Pharmaceutics. 2023 Feb;15(2):405. 49. Kopeček J. Hydrogel biomaterials: A smart future? Biomaterials. 2007 Dec 1;28(34):5185–92. 50. Arpa MD, Yoltaş A, Onay Tarlan E, Şenyüz CŞ, Sipahi H, Aydın A, et al. New therapeutic system based on hydrogels for vaginal candidiasis management: formulation–characterization and in vitro evaluation based on vaginal irritation and direct contact test. Pharmaceutical Development and Technology. 2020 Nov 25;25(10):1238–48. 51. Ahmed EM. Hydrogel: Preparation, characterization, and applications: A review. Journal of Advanced Research. 2015 Mar 1;6(2):105–21. 52. Liu RH, Yu Q, Beebe DJ. Fabrication and characterization of hydrogel-based microvalves. Journal of Microelectromechanical Systems. 2002 Feb;11(1):45–53. 53. Farida S, Sahlan M, Rohmatin E, Adawiyah R. The beneficial effect of Indonesian propolis wax from Tetragonula sp. as a therapy in limited vaginal candidiasis patients. Saudi Journal of Biological Sciences. 2020 Jan 1;27(1):142–6. 54. Riaz A, Hendricks S, Elbrink K, Guy C, Maes L, Ahmed N, et al. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models. AAPS PharmSciTech. 2020 Jul 6;21(5):185. 55. dos Santos MK, Kreutz T, Danielli LJ, De Marchi JGB, Pippi B, Koester LS, et al. A chitosan hydrogel-thickened nanoemulsion containing Pelargonium graveolens essential oil for treatment of vaginal candidiasis. Journal of Drug Delivery Science and Technology. 2020 Apr 1;56:101527.
Article Sidebar
Published
Mar 30, 2023
Article Details
How to Cite
1.
Tushita Kaushik1, Gowthamarajan K1, Keerthi Kishan E1, Roshan P Rao1
‘PANORAMA VIEW OF IN-SITU GEL AND HYDROGEL-PERSONALIZED APPROACH FOR MANAGEMENT OF VAGINAL CANDIDIASIS.’
. 2023 Mar. 13;94(1): 1434-1449. Available from: https://mattioli.1885journals.com/article/2023/1434.html
Issue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.